Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARgamma and inhibition of ERK 1 / 2

Cancer Science
Hyun-Seuk MoonChong-su Cho

Abstract

Alpha-eleostearic acid (alpha-ESA) is known to suppress the growth in cancer cells although its underlying molecular mechanisms have not been fully elucidated. The present study was designed to elucidate and evaluate the anticancer mechanism of alpha-ESA on MCF-7 breast cancer cells. Also, an attempt was made to better understand the anticancer mechanism by which alpha-ESA activated PPARgamma and attenuated the ERK1/2 MAPK phosphorylation state. The MCF-7 breast cancer cell-line and nontumorigenic MCF-10A human mammary epithelial cells were treated with alpha-ESA and compared with negative control (without treatment) and positive control groups (treated with rosiglitazone), and changes of apoptosis-related molecules, PPARgamma and pERK1/2 were examined. In MCF-7 cells treated with alpha-ESA, we found that the expression of p53, p21, and Bax was up-regulated whereas expression of Bcl-2 and procaspase-9 was down-regulated. Moreover, nuclear translocation of PPARgamma by alpha-ESA positively correlated with inhibition of ERK1/2 activation. Our data suggest that alpha-ESA can be considered to be a PPARgamma agonist and thus a candidate for a chemotherapeutic agent against breast cancer.

References

Feb 3, 1999·Molecular Pharmacology·Y Y Mo, W T Beck
Jul 21, 2001·Journal of Molecular Endocrinology·L FajasJ Auwerx
Feb 1, 2002·The Journal of Biological Chemistry·Damu TangAlistair J Ingram
Jun 29, 2002·Cellular and Molecular Life Sciences : CMLS·A K HihiW Wahli
Sep 5, 2003·Journal of Nutritional Science and Vitaminology·Tsuyoshi TsuzukiTeruo Miyazawa
Mar 24, 2004·Genes & Development·Enrique SaezRonald M Evans
May 3, 2005·The Lancet Oncology·Jing Yuan Fang, Bruce C Richardson

❮ Previous
Next ❯

Citations

Jun 22, 2011·Journal of Natural Medicines·Tingting ZhangXiujie Wang
Apr 23, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ying LiuDong-Sheng Pei
May 15, 2012·Carcinogenesis·Graham Skelhorne-GrossChristopher J B Nicol
Feb 19, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Leticia García-AguilarMiguel A Zavala-Sánchez
Aug 13, 2013·International Journal of Cancer. Journal International Du Cancer·Anthony J ApostoliChristopher J B Nicol
Apr 25, 2014·Food & Function·Gao-Feng YuanDuo Li
Mar 13, 2016·Lipids·Alan A HennessyCatherine Stanton
May 26, 2016·Critical Reviews in Food Science and Nutrition·Ana L FontesLuís M Rodríguez-Alcalá
Feb 23, 2020·Journal of Translational Medicine·Wanting ShaoSophie Sixou
Jul 20, 2021·Journal of Ayurveda and Integrative Medicine·K N K RanasingheR P V J Rajapakse
May 10, 2019·Journal of Agricultural and Food Chemistry·Kaushik K Dhar DubeyAruna Kumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.